Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA

Liver International

Volumn 35, Issue 6, 2015, Pages 1692-1699

  Lu, Junfeng ^a   Zhang, Shibin ^a   Liu, Yali ^a   Du, Xiaofei ^a   Ren, Shan ^a   Zhang, Hua ^a   Ma, Lina ^a   Chen, Yue ^b   Chen, Xinyue ^a   Shen, Chengli ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chronic hepatitis B; Normal levels of ALT and high levels of HBV DNA; Pegylated interferon 2a; Pregnant woman

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; TELBIVUDINE; VIRUS DNA; ADENINE; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN; THYMIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHILDBIRTH; CHRONIC HEPATITIS B; DELIVERY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGICAL PARAMETERS; PREGNANT WOMAN; PROSPECTIVE STUDY; PUERPERIUM; SEROCONVERSION; SEROLOGY; SIDE EFFECT; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; HEPATITIS B, CHRONIC; PREGNANCY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; POSTPARTUM PERIOD; PREGNANCY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THYMIDINE; TREATMENT OUTCOME;

EID: 84929129472     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12753     Document Type: Article

References (35)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
3. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-7.
4. Cui F, Luo H, Wang F, et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine 2013; 31(Suppl. 9): J36-42.
5. Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J 2007; 120: 2157-8.
6. Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
7. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014; 146: 1240-8.
8. Lin HH, Chen PJ, Chen DS, et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol 1989; 29: 1-6.
9. Lin HH, Wu WY, Kao JH, Chen DS. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. J Gastroenterol Hepatol 2006; 21: 605-9.
10. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepatitis 2009; 16: 94-103.
11. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-21.
12. Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520-6.
13. Yu M, Jiang Q, Ji Y, et al. The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis 2012; 31: 2211-8.
14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
15. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
16. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S103-11.
17. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
18. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
19. Lok AS, Mcmahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
20. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401.
21. Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
22. Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection. J Gastroenterol Hepatol Res 2010; 40: 31-48.
23. Rolle L, Memarzadeh Tehran M, Morell-Garcia A, et al. Cutting edge: IL-10-producing regulatory B cells in early human pregnancy. Am J Reprod Immunol 2013; 70: 448-53.
24. Ter Borg MJ, Leemans WF, De Man RA, Janssen H L. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepatitis 2008; 15: 37-41.
25. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96-104.
26. Niro GA, Fontana R, Gioffreda D, et al. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis 2007; 39: 857-63.
27. Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepatitis 2011; 18: 580-6.
28. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-50.
29. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191: 1777-88.
30. Willberg CB, Ward SM, Clayton RF, et al. Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. PLoS ONE 2007; 2: e791.
31. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
32. Tan AT, Hoang LT, Chin D, et al. Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy. J Hepatol 2014; 60: 54-61.
33. Chen XY, Cao ZH, Liu YL, et al. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with alpha-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol 2012; 27: 481-6.
34. Zoutendijk R, Hansen BE, Van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-8.
35. Chen XYWY, Ma LN. Clinical study of telbivudine or (and) interferon treating chronic hepatitis B complicated with peripheral neuritis. J Chinese Philo 2009; 27: 53-5.